# Rivastigmine for Antimuscarinic Delirium

> **NCT06382649** · PHASE2 · SUSPENDED · sponsor: **Washington University School of Medicine** · enrollment: 42 (estimated)

## Conditions studied

- Anticholinergic Toxicity

## Interventions

- **DRUG:** Rivastigmine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06382649
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2026-11
- **Primary completion:** 2027-07
- **Final completion:** 2027-07
- **Target enrollment:** 42 (ESTIMATED)
- **Why stopped:** The RIVA-AM study was designed to evaluate treatment options when the gold standard treatment (physostigmine) was unavailable in the United States. Before RIVA-AM launched, the FDA acted to permit the importation of foreign physostigmine products.
- **Last updated:** 2026-04-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06382649

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06382649, "Rivastigmine for Antimuscarinic Delirium". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06382649. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*